Zenas BioPharma, Net Asset vs. Three Year Return
| ZBIO Etf | USD 9.25 0.09 0.98% |
For Zenas BioPharma, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zenas BioPharma, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zenas BioPharma, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zenas BioPharma,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zenas BioPharma, Common over time as well as its relative position and ranking within its peers.
Zenas |
The market value of Zenas BioPharma, Common is measured differently than its book value, which is the value of Zenas that is recorded on the company's balance sheet. Investors also form their own opinion of Zenas BioPharma,'s value that differs from its market value or its book value, called intrinsic value, which is Zenas BioPharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zenas BioPharma,'s market value can be influenced by many factors that don't directly affect Zenas BioPharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zenas BioPharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Zenas BioPharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zenas BioPharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zenas BioPharma, Common Three Year Return vs. Net Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Zenas BioPharma,'s current stock value. Our valuation model uses many indicators to compare Zenas BioPharma, value to that of its competitors to determine the firm's financial worth. Zenas BioPharma, Common is rated below average in net asset as compared to similar ETFs. It is rated below average in three year return as compared to similar ETFs . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zenas BioPharma,'s earnings, one of the primary drivers of an investment's value.Zenas Three Year Return vs. Net Asset
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Zenas BioPharma, |
| = | 68.18 M |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
Zenas BioPharma, |
| = | (33.04) % |
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
Zenas Three Year Return Comparison
Zenas BioPharma, is rated below average in three year return as compared to similar ETFs.
Zenas BioPharma, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Zenas BioPharma,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zenas BioPharma, will eventually generate negative long term returns. The profitability progress is the general direction of Zenas BioPharma,'s change in net profit over the period of time. It can combine multiple indicators of Zenas BioPharma,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.
Zenas Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Zenas BioPharma,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zenas BioPharma, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zenas BioPharma,'s important profitability drivers and their relationship over time.
| Net Asset vs Beta | ||
| One Year Return vs Three Year Return | ||
| Net Asset vs Last Dividend Paid | ||
| Equity Positions Weight vs Three Year Return |
Use Zenas BioPharma, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Zenas BioPharma, Pair Trading
Zenas BioPharma, Common Pair Trading Analysis
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Zenas BioPharma, position
In addition to having Zenas BioPharma, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Zenas Etf
To fully project Zenas BioPharma,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zenas BioPharma, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zenas BioPharma,'s income statement, its balance sheet, and the statement of cash flows.